サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1414273

血液腫瘍（ヘマトオンコロジー）検査の世界市場レポート 2024年

Hemato Oncology Testing Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
血液腫瘍（ヘマトオンコロジー）検査の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

血液腫瘍（ヘマトオンコロジー）検査の市場規模は近年急速に拡大しています。2023年の31億6,000万米ドルから2024年には35億9,000万米ドルに、CAGR13.6％で拡大します。過去の期間に見られた拡大は、がん罹患率の増加、認知度の向上とスクリーニングプログラム、医療支出の増加、個別化医療の採用、血液疾患の発生増加などの要因によるものです。

血液腫瘍検査市場規模は、今後数年で急成長が見込まれます。2028年にはCAGR 13.7％で59億8,000万米ドルに成長します。予測期間中に予想される成長は、個別化医療の動向、人工知能の統合、高齢者人口の増加、ゲノム研究の進歩、がんの早期発見に対する需要の増加などに起因しています。予測期間に予想される主な動向には、ゲノム検査における技術的進歩、非侵襲的検査のためのリキッドバイオプシーの採用、業界内の協力や提携、規制状況や標準化の検討、さまざまな技術における進行中の進歩などが含まれます。

予想される血液がんの罹患率の上昇は、血液がん検査市場の成長の原動力となると思われます。血液がんは、血液、骨髄、リンパ系に影響を及ぼす、血液に起因するがんの一群を包含し、白血病、リンパ腫、骨髄腫などの疾患が含まれます。これらの疾患は早期診断が重要であり、血液腫瘍検査はそのために極めて重要な役割を果たします。一例として、米国がん協会は、2023年には白血病が約59,610人の米国人に影響を与え、23,710人の死亡につながると予測しています。さらに、非ホジキンリンパ腫は米国で80,550人が罹患し、20,180人が死亡すると予測されています。したがって、血液がんの有病率の増加は、血液腫瘍検査市場を前進させる重要な要因です。

医療支出の増加は、当面、血液腫瘍検査市場拡大の触媒として作用すると予想されます。医療支出は、特定の地域または国において、一定期間中に医療部門に割り当てられる公的および私的な資金の総額を包含します。血液腫瘍検査における医療支出の賢明な配分は、診断精度の向上、個別化された治療法、造血器腫瘍の複雑な状況における患者の転帰の向上に寄与します。例えば、2022年9月現在、メディケア＆メディケイドサービスセンターは、国民医療費が2.7％増加し、2021年には4兆3,000億米ドル、一人当たり1万2,914米ドルに達し、GDPの18.3％を占めると予測していると報告しています。したがって、医療支出の増大は血液腫瘍検査市場を煽る重要な要因です。

2023年の血液腫瘍検査市場では北米が最大地域でした。アジア太平洋は、予測期間中に血液腫瘍検査世界市場レポートにおいて最も急成長する地域となる見込みです。血液腫瘍検査市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 市場促進要因・市場抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 市場規模と成長実績、2018～2023年
  • 市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

  • 世界の血液腫瘍検査市場、製品・サービス別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • アッセイキット・試薬
  • サービス
  • 世界の血液腫瘍検査市場、がんの種類別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 白血病
  • リンパ腫
  • 多発性骨髄腫
  • その他
  • 世界の血液腫瘍検査市場、技術別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • ポリメラーゼ連鎖反応（PCR）
  • 免疫組織化学（IHC）
  • 次世代シーケンス（NGS）
  • その他
  • 世界の血液腫瘍検査市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • 学術研究機関
  • その他

第7章 地域および国の分析

  • 世界の血液腫瘍検査市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の血液腫瘍検査市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 血液腫瘍検査市場の競合情勢
  • 血液腫瘍検査市場の企業プロファイル
    • F. Hoffmann-La Roche Ltd.
    • Abbott Laboratories
    • Thermo Fisher Scientific Inc.
    • Illumina Inc.
    • Icon plc

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

目次
Product Code: r11783

“Hemato Oncology Testing Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hemato oncology testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hemato oncology testing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The hemato oncology testing market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Product And Services: Assay Kits And Reagents; Services
  • 2) By Cancer Type: Leukemia; Lymphoma; Multiple Myeloma; Other Cancers
  • 3) By Technology: Polymerase Chain Reaction (PCR); Immunohistochemistry (IHC); Next-Generation Sequencing (NGS); Other Technologies
  • 4) By End User: Hospitals; Academic And Research Institutes; Other End Users
  • Companies Mentioned: F. Hoffmann-La Roche Ltd.; Abbott Laboratories; Thermo Fisher Scientific Inc.; Illumina Inc.; Icon plc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Hemato-oncology testing involves diagnostic procedures designed to identify symptoms of blood disorders and blood cancers. These tests play a crucial role in diagnosing conditions such as anemia, infections, hemophilia, blood-clotting disorders, and leukemia.

The primary products and services associated with hemato-oncology testing include assay kits, reagents, and testing services. Assay kits and reagents encompass instruments and chemicals utilized together to analyze specific substances. The testing procedures cover various cancer types, including leukemia, lymphoma, multiple myeloma, and others. The technologies employed for these tests include polymerase chain reaction (PCR), immunohistochemistry (IHC), next-generation sequencing (NGS), and other advanced techniques. The end-users of hemato-oncology testing include hospitals, academic and research institutes, and other healthcare entities.

The hemato oncology testing market research report is one of a series of new reports from The Business Research Company that provides hemato oncology testing market statistics, including hemato oncology testing industry global market size, regional shares, competitors with hemato oncology testing market share, detailed hemato oncology testing market segments, market trends, and opportunities, and any further data you may need to thrive in the hemato oncology testing industry. This hemato oncology testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hemato oncology testing market size has grown rapidly in recent years. It will grow from $3.16 billion in 2023 to $3.59 billion in 2024 at a compound annual growth rate (CAGR) of 13.6%. The expansion observed in the historical period can be attributed to factors such as the increasing incidence of cancer, growing awareness and screening programs, rising healthcare expenditure, the adoption of personalized medicine, and an increase in the occurrence of blood disorders.

The hemato oncology testing market size is expected to see rapid growth in the next few years. It will grow to $5.98 billion in 2028 at a compound annual growth rate (CAGR) of 13.7%. The anticipated growth in the forecast period can be attributed to trends in personalized medicine, the integration of artificial intelligence, a rising geriatric population, advancements in genomic research, and an increasing demand for early cancer detection. Key trends expected in the forecast period encompass technological advancements in genomic testing, the adoption of liquid biopsy for non-invasive testing, collaborations and partnerships within the industry, considerations of the regulatory landscape and standardization, and ongoing progress in various technologies.

The anticipated rise in the incidence of hematologic cancer is set to be a driving force behind the growth of the hemato-oncology testing market. Hematologic cancer encompasses a group of cancers originating in the blood, affecting the blood, bone marrow, and lymphatic system, including conditions such as leukemia, lymphoma, and myeloma. Early diagnosis is crucial for these diseases, and hemato-oncology testing plays a pivotal role in achieving this. As an illustration, the American Cancer Society estimates that in 2023, leukemia is expected to impact approximately 59,610 Americans, leading to 23,710 deaths. Additionally, non-Hodgkin lymphoma is projected to affect 80,550 individuals in the United States, resulting in 20,180 deaths. Hence, the increasing prevalence of hematologic cancers is a significant driver propelling the hemato-oncology testing market forward.

The growth in healthcare expenditure is anticipated to act as a catalyst for the expansion of the hemato-oncology testing market in the foreseeable future. Healthcare expenditure encompasses the total funds, both public and private, allocated to the healthcare sector within a specific geographical area or country during a given period. The judicious allocation of healthcare spending in hemato-oncology testing contributes to improved diagnostic accuracy, personalized treatment methods, and enhanced patient outcomes in the intricate landscape of hematopoietic tumors. For example, as of September 2022, the Centers for Medicare & Medicaid Services reported an expected 2.7 percent increase in national health spending, reaching $4.3 trillion in 2021, or $12,914 per person, constituting 18.3% of GDP. Therefore, the escalating healthcare expenditure is a key driver fueling the hemato-oncology testing market.

A prominent trend in the hemato-oncology testing market is the innovation of products by major companies to sustain their market position. These innovations include Sysmex CLIA-validated liquid biopsy tests, exemplifying cutting-edge solutions for diagnosing Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML). Launched by Sysmex Inostics in October 2021, this liquid biopsy test utilizes targeted Next Generation Sequencing (NGS) technology, offering exceptional sensitivity to detect even minute traces of cancer cells post-initial therapy.

Major companies in the hemato-oncology testing market are adopting a strategic partnership approach to supplement their hemato-oncology portfolio. Strategic partnerships involve leveraging mutual strengths and resources to achieve shared benefits and success. An instance of this is the collaboration between Servier Laboratories and QIAGEN N.V. to develop an mIDH1 companion diagnostic test. This test is intended to complement Servier's AML therapies by swiftly identifying patients with IDH1 gene mutations using a PCR-based diagnostic test. QIAGEN, a Germany-based molecular diagnostics company, will develop and validate this test under the Master Cooperation Agreement.

In January 2023, Merck & Co. Inc., a leading US-based pharmaceutical company, acquired Imago BioSciences, Inc., a biotechnology company focusing on diagnostic and therapeutic products for hemato-oncology testing and related blood disorders. This acquisition aligns with Merck's commitment to fortify its presence in the hematology field by investing in innovative solutions and strengthening its pipeline.

Major companies operating in the hemato oncology testing market report are F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Illumina Inc., Icon plc, Invivoscribe Inc., Qiagen N.V., Bio-Rad Laboratories Inc., Archerdx Inc., ARUP Laboratories Inc., Asuragen Inc., Adaptive Biotechnologies Corp., Cepheid Inc., EntroGen Inc., CORE Diagnostics Inc., Genoptix Inc., GenPath Diagnostics, NeoGenomics Laboratories Inc., Siemens AG, Sysmex Corporation, Laboratory Corporation of America Holdings, Agilent Technologies, Danaher Corporation, Grifols SA, Exact Sciences Corporation, Guardant Health Corp., Personal Genome Diagnostics Inc., Diaorin SpA, HTG Molecular Diagnostics Inc., Admera Health

North America was the largest region in the hemato oncology testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global hemato oncology testing market report during the forecast period. The regions covered in the hemato oncology testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the hemato oncology testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The hemato oncology testing market consists of revenues earned by entities by providing sampling and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The hemato-oncology testing market also includes the sales of consumables and instruments which are used to provide hemato-oncology testing services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Hemato Oncology Testing Market Characteristics

3. Hemato Oncology Testing Market Trends And Strategies

4. Hemato Oncology Testing Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On the Market
  • 4.2. Ukraine-Russia War Impact On the Market
  • 4.3. COVID-19 Impact On the Market

5. Global Hemato Oncology Testing Market Size and Growth

  • 5.1. Global Hemato Oncology Testing Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Hemato Oncology Testing Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Hemato Oncology Testing Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Hemato Oncology Testing Market Segmentation

  • 6.1. Global Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Assay Kits And Reagents
  • Services
  • 6.2. Global Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Leukemia
  • Lymphoma
  • Multiple Myeloma
  • Other Cancers
  • 6.3. Global Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • Next-Generation Sequencing (NGS)
  • Other Technologies
  • 6.4. Global Hemato Oncology Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Academic And Research Institutes
  • Other End Users

7. Hemato Oncology Testing Market Regional And Country Analysis

  • 7.1. Global Hemato Oncology Testing Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Hemato Oncology Testing Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Hemato Oncology Testing Market

  • 8.1. Asia-Pacific Hemato Oncology Testing Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Hemato Oncology Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Hemato Oncology Testing Market

  • 9.1. China Hemato Oncology Testing Market Overview
  • 9.2. China Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Hemato Oncology Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Hemato Oncology Testing Market

  • 10.1. India Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Hemato Oncology Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Hemato Oncology Testing Market

  • 11.1. Japan Hemato Oncology Testing Market Overview
  • 11.2. Japan Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Hemato Oncology Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Hemato Oncology Testing Market

  • 12.1. Australia Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Hemato Oncology Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Hemato Oncology Testing Market

  • 13.1. Indonesia Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Hemato Oncology Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Hemato Oncology Testing Market

  • 14.1. South Korea Hemato Oncology Testing Market Overview
  • 14.2. South Korea Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Hemato Oncology Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Hemato Oncology Testing Market

  • 15.1. Western Europe Hemato Oncology Testing Market Overview
  • 15.2. Western Europe Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Hemato Oncology Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Hemato Oncology Testing Market

  • 16.1. UK Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Hemato Oncology Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Hemato Oncology Testing Market

  • 17.1. Germany Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Hemato Oncology Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Hemato Oncology Testing Market

  • 18.1. France Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Hemato Oncology Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Hemato Oncology Testing Market

  • 19.1. Italy Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Hemato Oncology Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Hemato Oncology Testing Market

  • 20.1. Spain Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Hemato Oncology Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Hemato Oncology Testing Market

  • 21.1. Eastern Europe Hemato Oncology Testing Market Overview
  • 21.2. Eastern Europe Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Hemato Oncology Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Hemato Oncology Testing Market

  • 22.1. Russia Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Hemato Oncology Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Hemato Oncology Testing Market

  • 23.1. North America Hemato Oncology Testing Market Overview
  • 23.2. North America Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Hemato Oncology Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Hemato Oncology Testing Market

  • 24.1. USA Hemato Oncology Testing Market Overview
  • 24.2. USA Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Hemato Oncology Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Hemato Oncology Testing Market

  • 25.1. Canada Hemato Oncology Testing Market Overview
  • 25.2. Canada Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Hemato Oncology Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Hemato Oncology Testing Market

  • 26.1. South America Hemato Oncology Testing Market Overview
  • 26.2. South America Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Hemato Oncology Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Hemato Oncology Testing Market

  • 27.1. Brazil Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Hemato Oncology Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Hemato Oncology Testing Market

  • 28.1. Middle East Hemato Oncology Testing Market Overview
  • 28.2. Middle East Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Hemato Oncology Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Hemato Oncology Testing Market

  • 29.1. Africa Hemato Oncology Testing Market Overview
  • 29.2. Africa Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Hemato Oncology Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Hemato Oncology Testing Market Competitive Landscape And Company Profiles

  • 30.1. Hemato Oncology Testing Market Competitive Landscape
  • 30.2. Hemato Oncology Testing Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche Ltd.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Abbott Laboratories
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Thermo Fisher Scientific Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Illumina Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Icon plc
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Hemato Oncology Testing Market Competitive Benchmarking

32. Global Hemato Oncology Testing Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Hemato Oncology Testing Market

34. Hemato Oncology Testing Market Future Outlook and Potential Analysis

  • 34.1 Hemato Oncology Testing Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Hemato Oncology Testing Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Hemato Oncology Testing Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer